Endocrinology

Predicting the outcome for newborns with congenital hyperinsulinism

Babies born with congenital hyperinsulinism (CHI) are at risk of suffering from permanent brain damage and life-long disability.

newborn baby feet
Source: Unsplash/Ignacio Campo

Yet some will go on to suffer more severely than others as a result of their disease profile, report the researchers in an article published in Frontiers in Endocrinology. The research team have found that it is possible to predict when and how the disease may affect the child in the long-term. “One of the problems facing clinicians is that it is really difficult to predict which babies will have problems after surgical treatment. Our new data give some important clues that will help clinicians to know how much extra care each baby is likely to need”, explains Dr Karen Cosgrove, a member of the research team from The University of Manchester. Although generally rare, affecting just 1 in 50,000 children in the UK, CHI can be as common as cystic fibrosis (1 in 2,500) in children of European Jewish descent or when born into communities where cousins marry.

Although the impact of these findings is limited to centres with surgical resources, for those centres the data is immediately applicable and translatable clinically

Mark Dunne

Up until now, scientists have understood that there are two main subtypes of the disease - known as diffuse and focal. Diffuse CHI affects the entire pancreas, whilst focal CHI affects just one area of the organ, forming a focal lesion. The team from Manchester now understand that focal CHI can be further categorised into two types- spreading focal lesions and isolated focal lesions. Spreading focal lesions are generally larger and spread outwards into areas of healthy cells. Isolated focal lesions, on the other hand, have a capsule around them which keeps the diseased cells separate from healthy cells.

The research team investigated the cases of 25 infants with focal CHI to see how the two types of lesions influenced their long-term outcomes. They found that babies with spreading focal lesions suffered more severely from the disease and were diagnosed earlier. These infants were more likely to suffer brain damage which permanently affected their development, learning and behaviour. In contrast, in infants with isolated lesions, the disease was diagnosed later and surgery to remove the lesion was less complicated.

These new data help to explain why new-born babies diagnosed with the same disease may go on to have very different outcomes and could influence the way clinicians choose to manage each new case of CHI. “Although the impact of these findings is limited to centres with surgical resources, for those centres the data is immediately applicable and translatable clinically” explains Professor Mark Dunne from The University of Manchester and lead author on the study.


Source: University of Manchester

02.04.2019

More on the subject:
Read all latest stories

Related articles

Photo

Gender Medicine

“Inclusion of women in studies and guidelines must be increased”

Women and men are different – nobody would argue with this statement. However, in medicine, gender plays a subordinate role. Neither research, prevention nor therapy adequately reflect this…

Photo

Covid-19's impact on studies

Clinical trials during the pandemic: lessons for future cancer research

The continuing corona virus epidemic has impacted strongly on cancer care and research, including the delay of treatments and diagnoses as well as on trials of new therapies, and the shift in…

Photo

Fewer heart surgeries, more patient deaths

Landmark study examines 'Covid effect' on cardiac surgery

The most deadly global health crisis in a century has resulted in a substantial decline in overall heart surgery volume and an unexplained increase in deaths after coronary artery bypass grafting,…

Related products

Sarstedt – Low DNA Binding Micro Tubes

Research Use Only (RUO)

Sarstedt – Low DNA Binding Micro Tubes

SARSTEDT AG & CO. KG
Shimadzu – CLAM-2030

Research Use Only (RUO)

Shimadzu – CLAM-2030

Shimadzu Europa GmbH
Subscribe to Newsletter